treatment Dotaz Zobrazit nápovědu
This paper reports on the antitumor activity of BS RNase on human melanoma and mouse seminoma. Human melanoma cells established in culture were extremely susceptible to BS RNase, administered in concentrations ranging from 1-100 microg/ml. Concentrations of BS RNase over 10 microg/ml caused complete inhibition of cell growth. Bovine pancreatic ribonuclease (RNase A), a prototype of the ribonuclease superfamily, did not exert any effect under these conditions. Based on our previous results, athymic mice bearing human melanoma or mouse seminoma were treated with intratumoral administration of BS RNase (12.5 mg/kg b.w.). This dose was injected for five consecutive days excluding weekends. The intratumoral administration of BS RNase to nude mice bearing human melanoma showed a significant antitumor effect. There were no tumors seen in eighty percent of mice treated for three weeks, and tumors in the other mice diminished significantly. After some delay the tumors started to regrow. Prolonging of the treatment to five weeks had a similar effect. The effect of BS RNase on mouse seminoma was well pronounced. Five to seven doses of BS RNase were sufficient to eliminate tumors in all treated mice. However, as in the previous experiment, the growth of tumor tissue later reappeared.
- MeSH
- endoribonukleasy terapeutické užití MeSH
- lidé MeSH
- melanom farmakoterapie MeSH
- myši nahé MeSH
- myši MeSH
- nádorové buňky kultivované MeSH
- pankreatická ribonukleasa terapeutické užití MeSH
- protinádorové látky terapeutické užití MeSH
- screeningové testy protinádorových léčiv MeSH
- seminom farmakoterapie MeSH
- testikulární nádory farmakoterapie MeSH
- viabilita buněk účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- endoribonukleasy MeSH
- pankreatická ribonukleasa MeSH
- protinádorové látky MeSH
- ribonuclease SPL MeSH Prohlížeč